At A Glance:

It’s no surprise that doctors are enthusiastic about the new CGRP class of migraine prevention drugs currently under development. More than 36 million Americans suffer from migraine attacks; of these, about 4 million have chronic migraine.

Download PDF
Indication:

Migraine

Enrollment time saved: 7 months
Randomized patients delivered: 56%
See the results
Case Study

AES Shortens Timelines by up to 20 Months for a Uterine Fibroid Program

VIEW CASE STUDY >
Case Study

AES Helped to Put a Sponsor at the Forefront of a Chronic Disease Market

VIEW CASE STUDY >
Case Study

AES saves up to 76 months of enrollment time for this pediatric depression program

VIEW CASE STUDY >
Case Study

Thanks to AES, a Sponsor Won its Race to Market with a New Class of OIC Drug

VIEW CASE STUDY >
Case Study

AES Saves More than 4 Months of Enrollment Time and $2.2 Million for Phase III Atopic Dermatitis Study

VIEW CASE STUDY >